The study covers a detailed analysis segmented by key business segments i.e. by type (Phytocannabinoids, Endocannabinoids and Synthetics) , by application (Medical and Recreational) and major geographies. Research Analyst at AMA predicts that North America Players will contribute to the maximum growth of Global Cannabinoid-based Products for Cancer market throughout the predicted period.
What is Cannabinoid-based Products for Cancer?
Cancer can be treated using cannabinoid medications, which are naturally occurring recreational substances used to treat anorexia, chronic pain, and nausea and vomiting. The term "cannabinoid" refers to a class of medications that share structural similarities with tetrahydro cannabinoids. Pharma companies make it to treat a variety of conditions, including various chronic and acute migraines, sclerosis, seizures, rheumatoid arthritis, and more. Due to rising demand for cannabis medications to treat chronic pain in various indications, the Cannabinoid Drugs market is likely to rise significantly in the approaching years. Furthermore, the end-user of Cannabinoid Drugs is expected to be influenced by healthcare expenditure in the field of dermatology, which is backed by FDA approvals.
The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the markets competitive landscape and offers information on the products offered by various leading companies. Additionally, this Cannabinoid-based Products for Cancer market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.
The report offers several leading Players, including:
- GW Pharmaceuticals (United Kingdom)
- Canopy Growth Corporation (Canada)
- AbbVie Inc (United States)
- Bausch Health (Canada)
- Medical Marijuana, Inc. (United States)
- Insys Therapeutics, Inc. (United States)
- Stenocare (Denmark)
September 2020 – AbbVie Inc. ABBV announced that it has inked a global collaboration deal with China’s I-Mab IMAB for the development and commercialization of the latter’s lemzoparlimab (also known as TJC4) to treat multiple types of cancers
the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. The agency has, however, approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These approved drug products are only available with a prescription from a licensed healthcare provider. Importantly, the FDA has not approved any other cannabis, cannabis-derived, or cannabidiol (CBD) products currently available on the market.
Several Benefits offered by these Products
- Various Product regulations and Marketing Regulations
- Cannabis is Still Banned in Several Countries
Increase in R&D and Technological Advantages
Key highlights of the Global Cannabinoid-based Products for Cancer market Study:
CAGR of the market during the forecast period 2020-2026
In-depth information on growth factors that will accelerate the Cannabinoid-based Products for Cancer market in next few years.
Detailed Insights on futuristic trends and changing consumer behaviour
Forecast of the Global Cannabinoid-based Products for Cancer market size and its contribution to the parent market by type, application and by country.
A broad view of customer demand
Uncover markets competitive landscape and in-depth information on various Players
Comprehensive information about factors that will challenge the growth of Cannabinoid-based Products for Cancer Players
Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
A tipping point in globalization
A major slowdown in Western economies
Significant shifts in technology and cost structure
The challenges of regulatory compliance
New forms of competition developing
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cannabinoid-based Products for Cancer market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cannabinoid-based Products for Cancer market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Medical Companies, Pharmaceutical Companies, Medical Research Companies, Hospitals, Regulatory Bodies, Government Bodies and Others.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. Where the Cannabinoid-based Products for Cancer industry is heading?
Cannabinoid-based Products for Cancer Market is heading robustly to achieve new growth cycle.2. Is Cannabinoid-based Products for Cancer market is changing from growth to value?
The Concentration Rate of Global Cannabinoid-based Products for Cancer market is dominated by North America Players to generate healthy valuation by 2026. 3. Who are the key players profiled in the Cannabinoid-based Products for Cancer Market?
Companies that are profiled in Global Cannabinoid-based Products for Cancer Market are GW Pharmaceuticals (United Kingdom), Canopy Growth Corporation (Canada), AbbVie Inc (United States), Bausch Health (Canada), Medical Marijuana, Inc. (United States), Insys Therapeutics, Inc. (United States) and Stenocare (Denmark) etc.